SCHEMBL7180792

SCHEMBL7180792

CCCCC(CC)COc1ccc(PC(=O)c2c(C)cc(C(C)(C)C)cc2C)c(C)c1.[LiH]

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 2/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
GAA P10253 1/20 0.36
XBP1 P17861 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
ALDH1A1 P00352 4/20 0.36
CYP3A4 P08684 4/20 0.36
CA2 P00918 1/20 0.36
TSHR P16473 3/20 0.35
MAPK1 P28482 2/20 0.35
TDP1 Q9NUW8 2/20 0.35
LMNA P02545 3/20 0.34
HSD17B10 Q99714 2/20 0.34
PPARG P37231 1/20 0.34
PPARA Q07869 1/20 0.34
PRSS1 P07477 1/20 0.33
PRSS2 P07478 1/20 0.33
PRSS3 P35030 1/20 0.33
PPARD Q03181 3/20 0.33
ITGB1 P05556 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7188305 0.92 ALDH1A1 (0.35) ATML3MBTL1GAAXBP1NPSR1
SCHEMBL7180427 0.91 ITGB1 (0.38) ATML3MBTL1GAAXBP1NPSR1
SCHEMBL7180852 0.89 ALDH1A1 (0.40) ATMALDH1A1CYP3A4CA2TSHR
SCHEMBL7182201 0.88 LMNA (0.38) ATML3MBTL1GAAXBP1NPSR1
SCHEMBL7185436 0.88 ALDH1A1 (0.37) ATML3MBTL1GAAXBP1NPSR1
SCHEMBL7179994 0.86 THRB (0.39) PPARGPPARAPPARDITGB1ITGA4
SCHEMBL7182729 0.85 ALDH1A1 (0.41) ALDH1A1CYP3A4CA2TSHRMAPK1
SCHEMBL7177466 0.84 THRB (0.42) TSHRITGB1ITGA4
SCHEMBL7186466 0.84 TDP1 (0.41) ALDH1A1CYP3A4CA2TSHRMAPK1
SCHEMBL7188923 0.84 ALDH1A1 (0.36) ATML3MBTL1GAAXBP1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 ATM 2823/4885L3MBTL1 302/4885GAA 4753/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 ATM 2935/4885L3MBTL1 126/4885GAA 4793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.